Dogwood Therapeutics, Inc. 8K

Dogwood Therapeutics announced Q1 2026 results, key clinical milestones for Halneuron and SP16, a new global partnership for legacy antiviral assets worth up to $100 million, and cash runway into Q4 2026.

Dogwood Therapeutics, Inc. reported its unaudited financial results for the quarter ended March 31, 2026, highlighted by continued Phase 2b enrollment progress for its lead candidate Halneuron in chemotherapy-induced neuropathic pain, FDA acceptance of an IND for SP16 to advance into a fully NCI-funded Phase 1b trial for chemotherapy-induced pain and neuropathy starting mid‑2026, and execution of a worldwide development and commercialization partnership for its legacy antiviral assets with potential value of up to $100 million for Dogwood and its current and former shareholders. The company completed a financing of up to $26.9 million in January 2026 (with $12.5 million received to date), ended the quarter with $13.2 million in cash providing runway into Q4 2026, and reported a net loss attributable to common stockholders of $5.0 million (or $0.15 per share), compared to a $12.2 million net loss (or $8.45 per share) in the prior-year quarter.

Filing Facts

CIK

1818844

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-060747

Alert Tier

6